Showing results (11-20 of 62) with videos related to
Sort By:
Pageof 7
Arthritis Care & Research|September 24, 2017
Timing and Impact of Decisions to Adjust Disease-Modifying Antirheumatic Drug Therapy for Rheumatoid Arthritis Patients With Active DiseaseYomei Shaw, Chung-Chou H Chang, Marc C Levesque, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 24, 2014
Complement component C5a permits the coexistence of pathogenic Th17 cells and type I IFN in lupusSudesh Pawaria, Kritika Ramani, Kelly Maers, et al.Arthritis Research & Therapy|May 19, 2016
Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarkerYong Gil Hwang, Goundappa K Balasubramani, Ilinca D Metes, et al.Arthritis Care & Research|June 29, 2012
Do patients with juvenile idiopathic arthritis in clinical remission have evidence of persistent inflammation on 3T magnetic resonance imaging?Amanda Brown, Raphael Hirsch, Tal Laor, et al.Arthritis Care & Research|June 3, 2017
Rheumatoid Arthritis Patients' Motivations for Accepting or Resisting Disease-Modifying Antirheumatic Drug Treatment RegimensYomei Shaw, Ilinca D Metes, Kaleb Michaud, et al.Leukemia Research|July 26, 2005
Chronic lymphocytic leukemia cell CD38 expression and inducible nitric oxide synthase expression are associated with serum IL-4 levelsMarc C Levesque, Youwei Chen, Bethany E Beasley, et al.Rheumatology (Oxford, England)|December 20, 2014
Anti-signal recognition particle autoantibody ELISA validation and clinical associationsRohit Aggarwal, Chester V Oddis, Danielle Goudeau, et al.Rheumatology (Oxford, England)|February 19, 2016
Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximabRohit Aggarwal, Chester V Oddis, Danielle Goudeau, et al.Rheumatology (Oxford, England)|November 21, 2013
Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validationRohit Aggarwal, Chester V Oddis, Danielle Goudeau, et al.Clinical Immunology (Orlando, Fla.)|March 3, 2007
Guidelines for assessing immunocompetency in clinical trials for autoimmune diseasesR John Looney, Betty Diamond, V Michael Holers, et al.Pageof 7